Literature DB >> 5104098

Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).

N S Sharpless, A D Ericsson, D S McCann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5104098     DOI： 10.1212/wnl.21.5.540

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

Review 1.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

2.  [Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].

Authors:  W Gehlen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974-04-09

3.  Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.

Authors:  K Baraczka; M I Fekete; B Kanyicska
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

4.  Idiopathic orthostatic hypotension treated with levodopa and MAO inhibitor: a preliminary report.

Authors:  J Sharpe; A Marquez-Julio; P Ashby
Journal:  Can Med Assoc J       Date:  1972-08-19       Impact factor: 8.262
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.